Skip to content
Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
About Us
APPROACH
CAREERS
LICENSING
CONTACT US
Focus Areas
IMMUNOLOGY
Pipeline
ALL ASSETS
IL-13 x TSLP
Updates
ALL UPDATES
PRESS RELEASES
VIDEOS
Investors
INVESTOR OVERVIEW
PRESS RELEASES
EVENTS & PRESENTATIONS
STOCK INFORMATION
FINANCIALS & FILINGS
Back to Resources
Articles
January 9, 2026
Vial is geared up to attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
Contact
Information
E:
contact@vial.com
S:
Linkedin
,
X
Join our mail list
"
*
" indicates required fields
Your email
*
Send
Δ
Get in touch!
Compose the future with us
"
*
" indicates required fields
Phone
This field is for validation purposes and should be left unchanged.
Name
*
Email
*
Comment
Δ
Contact Us
X/Twitter
This field is for validation purposes and should be left unchanged.
Name
(Required)
First
Last
Work email
(Required)
Phone
Company
Which best describes you?
(Required)
Which best describes you?*
Sponsor (Clinical Stage)
Sponsor (Preclinical Stage - FIH trial within 6 months)
Sponsor (Preclinical Stage - FIH trial in 6+ months)
Clinic/Site
Other
Message
By submitting, you are agreeing to our
terms
 andÂ
privacy policy
Δ
Clear search querie